MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Cerrado

2.64 5.6

Resumen

Variación precio

24h

Actual

Mínimo

2.5

Máximo

2.71

Métricas clave

By Trading Economics

Ingresos

-6.4M

-53M

Ventas

-9.6M

47M

BPA

-0.02

Margen de beneficio

-112.813

Empleados

580

EBITDA

-28M

-49M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+90.87% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

106M

880M

Apertura anterior

-2.96

Cierre anterior

2.64

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

2 jul 2025, 17:03 UTC

Principales Movimientos del Mercado

Furniture Companies Rise on U.S. Trade Deal With Vietnam

2 jul 2025, 15:18 UTC

Principales Movimientos del Mercado

Mogo Shares Rally After Embrace of Bitcoin Into Holdings, Operations

2 jul 2025, 23:45 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 jul 2025, 23:45 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2 jul 2025, 23:40 UTC

Charlas de Mercado

Gold Edges Lower Amid Hopes for More Trade Deals -- Market Talk

2 jul 2025, 21:01 UTC

Adquisiciones, fusiones, absorciones

AT&T Completes Sale of Entire Remaining 70% Stake in DIRECTV to TPG >T

2 jul 2025, 21:01 UTC

Adquisiciones, fusiones, absorciones

AT&T and TPG Close DIRECTV Transaction

2 jul 2025, 20:26 UTC

Ganancias

Rivian Stock Drops on Sales Decline. The Stakes Are High for the Rest of 2025. -- Barrons.com

2 jul 2025, 20:22 UTC

Charlas de Mercado

Gold Rises Following Weak ADP Payroll Reading -- Market Talk

2 jul 2025, 20:13 UTC

Charlas de Mercado

Oil Price Expectations Stable in Dallas Fed Survey -- Market Talk

2 jul 2025, 19:09 UTC

Charlas de Mercado

Oil Futures Bounce in Defiance of Downbeat Data -- Market Talk

2 jul 2025, 19:08 UTC

Charlas de Mercado

Dollar Trims Gains as Investors Brace for Cooling Jobs Market -- Market Talk

2 jul 2025, 19:01 UTC

Charlas de Mercado

U.S. Natural Gas Ticks Up Ahead of Storage Data -- Market Talk

2 jul 2025, 18:08 UTC

Charlas de Mercado

Fossil Fuels Rule Energy Roost As U.S. Marks Independence -- Market Talk

2 jul 2025, 17:06 UTC

Adquisiciones, fusiones, absorciones

BCE: Maple Leafs, Raptors Rights Access Through Long-Term Agreement With Rogers, Subject to League Approvals

2 jul 2025, 17:05 UTC

Adquisiciones, fusiones, absorciones

BCE: Access to Content Rights for Toronto Maple Leafs, Toronto Raptors on TSN Secured Through 2043/2044 Season

2 jul 2025, 17:04 UTC

Adquisiciones, fusiones, absorciones

BCE: Proceeds of MLSE Stake Sale to Support Financing of Acquisition of Ziply Fiber

2 jul 2025, 17:04 UTC

Adquisiciones, fusiones, absorciones

BCE Inc. Concludes Sale of Minority Stake in Maple Leaf Sports & Entertainment

2 jul 2025, 17:02 UTC

Adquisiciones, fusiones, absorciones

Rogers Communications: Now Largest Owner With 75% Interest in Maple Leaf Sports & Entertainment

2 jul 2025, 17:02 UTC

Adquisiciones, fusiones, absorciones

Rogers Communications Closes Deal to Buy BCE's 37.5% Stake in Maple Leaf Sports & Entertainment for C$4.7B

2 jul 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

2 jul 2025, 16:20 UTC

Charlas de Mercado

Cushing Crude Stock Slide Keeps Bid in WTI -- Market Talk

2 jul 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

2 jul 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

2 jul 2025, 16:11 UTC

Charlas de Mercado

Copper Prices Hold Higher on Supply Disruption, Tariff Uncertainty -- Market Talk

2 jul 2025, 16:09 UTC

Charlas de Mercado

Gold Futures Rise, Recouping Some Losses -- Market Talk

2 jul 2025, 15:59 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, Centene, Apple, Adobe, Rigetti Computing, Greenbrier, and More -- Barrons.com

2 jul 2025, 15:17 UTC

Charlas de Mercado

Oil Market to Keep Close Watch on U.S. Payrolls -- Market Talk

2 jul 2025, 15:08 UTC

Charlas de Mercado

Luxury Sector Should Report a Slowdown -- Market Talk

2 jul 2025, 15:00 UTC

Adquisiciones, fusiones, absorciones

Glencore: Merger of Viterra With Bunge Global Closed

Comparación entre iguales

Cambio de precio

Maravai LifeSciences Holdings Inc (Class A) Esperado

Precio Objetivo

By TipRanks

90.87% repunte

Estimación a 12 meses

Media 4.6 USD  90.87%

Máximo 7 USD

Mínimo 2 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Maravai LifeSciences Holdings Inc (Class A) Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

4

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.02 / 2.115Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.